We are very pleased to have Vishwas Paralkar join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic. Cybrexa Therapeutics, a start-up cancer...read more
“It’s really like a heat-seeking missile toward tumors,” Yale physician-scientist and Cybrexa’s chief scientific adviser, Dr. Ranjit Bindra, tells the Hartford Courant. “I know it sounds over the top but we’re really re-writing the rules of what makes a drug good and...read more
HartfordBusiness.com recently published a Q&A with Cybrexa's Per Hellsund about fundraising, and finding success in biotech startups. Read the full article here....read more
Read the write-up about Cybrexa's cancer treatment breakthrough in Yale's Centerpoint...read more
Financing supports development of new class of cancer therapies. New Haven, Conn., June __, 2017 Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has secured a Series B round of financing in the amount of $6 million. Connecticut...read more
Below are links to coverage of the high-impact DNA repair research findings by our Scientific Founders.
5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731